Spotlight On... Seqirus to build new U.K. manufacturing outpost; GSK scouts for new CEO; GeoVax to collaborate with U.S. Army research institute; and more...

Seqirus--the world's second largest flu vaccine player formed from CSL's purchase of Novartis' ($NVS) flu vaccines--is expanding in the U.K. It'll spend £15.3 million ($21.3 million) on a new flu vaccine manufacturing site in Speke, an announcement the company made as it opened a £6.8 million warehouse there. The company is the second largest flu vaccine player, behind Sanofi ($SNY), with more than 2,000 employees worldwide. More from FiercePharmaManufacturing

> GlaxoSmithKline ($GSK) is starting a search for a new CEO. Story

> GeoVax announced plans to work with the United States Army Medical Research Institute of Infectious Diseases on a vaccine effort against hemorrhagic fever viruses. Release

> Researchers at Oxford University have begun a clinical trial of a prostate cancer vaccine candidate, aiming to vaccinate 48 men with low or intermediate prostate cancer risk to test safety and immune responses. Release

> A team led by University of Exeter in the U.K. has developed a vaccine with the potential to protect from melioidosis, or Whitmore's disease, an often fatal disease in tropical regions. Release

Suggested Articles

Having struck two COVID-19 vaccine supply deals already, EU officials are in discussions with Novavax, as well.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.